NY-ESO-1 expression as an inducible chemosensitivity marker

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1056577

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Immunotherapy is a new concept treatment for lung cancer. Cancer testis antigen (CTA, eg NY-ESO-1) is an immunogenic molecule that was related with poor outcomes, but our recent studies have found that tumours that express NY-ESO-1 are more responsive to chemotherapy. We are also able to induce expression of NY-ESO-1 in cells that do not normally express it using demethylating agents. We aim to determine if we can increase the response to chemotherapy by using these drugs in combination.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2014

Funding Scheme: Postgraduate Scholarships

Funding Amount: $113,237.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chemotherapy | epigenetics | immunotherapy | lung cancer | oncology

Related Links